Henghui Zhang

8PUBLICATIONS
47CO-AUTHORS
Molecular targetsPredictive and prognostic markersInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 27, 2024
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.

Yanni Wang, Chang Liu, Huan Chen

|Jul 14, 2023
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.

Tao Jiang, Qiqi Jin, Jiahao Wang

|Jan 20, 2022
Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer.

Xueying Wu, Chenyang Zhang, Henghui Zhang

|Jan 14, 2022
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade.

Shuhang Wang, Pei Yuan, Beibei Mao

|Jun 02, 2021
Single cell transcriptome revealed tumor associated antigen (TAA) profile in lung adenocarcinoma (LUAD).

Fang Lv, Xueying Wu, Jin Song

|Feb 24, 2021
Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers.

Chuanhua Zhao, Lihong Wu, Dandan Liang

Pageof 2

Frequent Collaborators

1 joint publications

Rongjie Tao

1 joint publications

Jianming Ying

1 joint publications

Shugeng Gao

1 joint publications

Tao Jiang